dr. cole
Member
- Reaction score
- 47
On Friday I flew to Italy to discuss new follicle regeneration trials with Pietro Gentile, MD, Ph.D. and Chiara Insalaco, MD. After spending a year with me, Dr. Insalaco is now pursuing her Ph.D. at the University of Rome, Sapienza, while offering hair restoration in her private practice and her University appointment. While I returned on Monday, this is the first opportunity I've had to report on this very significant meeting because I resumed work immediately.
We are starting two new trials involving the combination of a stromal vascular fraction with high-quality PRP (PRL) and second will include follicle stem cells. We discussed the protocols for each study. Neither technology is currently available in the USA. While I hope to bring these to the USA, I do encourage patients in Italy to enroll in these protocols. Both protocols are cutting edge regenerative medicine.
The limitations on our entry into regenerative medicine in the USA is a primary reason I have chosen to open an office in Rome, Italy. We will obtain follicle stem cells through mechanical separation. We will combine my method of minimal depth extraction to remove follicles to avoid pollution of the cell pool with fibroblasts and adipocytes. The use of stromal vascular fraction (SVF) is highly limited in the USA. The combination of SVF and PRP or PRL has not been studied yet in hair loss.
While we hope to evaluate the benefit of injecting follicle stem cells, my primary focus is on an unlimited donor supply by reintroducing follicle stem cells into minimal depth extraction sites along with an extracellular matrix.
We are starting two new trials involving the combination of a stromal vascular fraction with high-quality PRP (PRL) and second will include follicle stem cells. We discussed the protocols for each study. Neither technology is currently available in the USA. While I hope to bring these to the USA, I do encourage patients in Italy to enroll in these protocols. Both protocols are cutting edge regenerative medicine.
The limitations on our entry into regenerative medicine in the USA is a primary reason I have chosen to open an office in Rome, Italy. We will obtain follicle stem cells through mechanical separation. We will combine my method of minimal depth extraction to remove follicles to avoid pollution of the cell pool with fibroblasts and adipocytes. The use of stromal vascular fraction (SVF) is highly limited in the USA. The combination of SVF and PRP or PRL has not been studied yet in hair loss.
While we hope to evaluate the benefit of injecting follicle stem cells, my primary focus is on an unlimited donor supply by reintroducing follicle stem cells into minimal depth extraction sites along with an extracellular matrix.